

Press Release

SuppreMol Closes EUR 15.5 M Series C Financing Round

Martinsried/Munich, Germany, December 1st, 2010 -- SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases, today announced the closing of a EUR 15.5 million Series C financing round. The round was led by MIG AG (Munich, Germany) with BioMedPartners AG (Basel, Switzerland) as co-lead. The other existing investors Santo Holding GmbH (Poecking, Germany), KfW Mittelstandsbank (Bonn, Germany), Bayern Kapital GmbH (Landshut, Germany) and Max-Planck-Gesellschaft (Munich, Germany) also participated in the round. The round was joined by FCP Biotech Holding GmbH (Graefelfing, Germany) as new investor.

SuppreMol will use the proceeds for the GMP production and further clinical studies of its lead candidate SM101, a recombinant human soluble Fc gamma receptor IIb for the treatment of Primary Immune Thrombocytopenia (ITP) and of Systemic Lupus Erythematosus (SLE). ITP is a serious bleeding condition characterized by deficient blood clotting due to auto-antibodies destroying the body's platelets. For the treatment of ITP, SM101 has been granted orphan drug designation in the European Union and in the US and has entered Phase Ib/IIa clinical studies early this year. SLE is a chronic inflammatory autoimmune disease of unknown etiology affecting multiple organs, which can lead to organ failure. SuppreMol plans to initiate a Phase IIa study in SLE mid next year. In addition, the funds will be used for the preclinical development of an anti-Fc γ RIIb monoclonal antibody, which, due to the different properties of this molecule compared to SM101, may have beneficial therapeutic potential in certain autoimmune diseases.

„The financing round will enable us to complete all our planned clinical studies plus the preclinical development of our monoclonal antibody and extends our runway well into 2013,“ said Dr Peter Buckel, CEO of SuppreMol. “By then, we hope to have clinical proof-of-concept in two autoimmune indications, providing us with a strong position for further strategic options.”

„SuppreMol has made impressive progress during the last two years in advancing its pipeline,“ said Dr Markus Hosang, General Partner at BioMedPartners. „The round now provides the basis for the next value enhancing milestones, as it will enable SuppreMol to conduct further clinical trials and to explore different indication areas with high market potential.”

###

Notes to Editors

About SuppreMol

SuppreMol is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases. The company is pioneering the development of soluble Fc gamma receptors (sFc γ Rs), which are recombinant autologous therapeutic proteins with a proven strong immunosuppressive potential. The company plans to develop sFc γ Rs for the treatment of Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) and other autoimmune conditions.

SuppreMol was founded in 2002 as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize for Chemistry in 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. The company has raised EUR 35.2 million in three financing rounds since May 2006 and received over EUR 2 million from BMBF research grants since 2007.

About SM101

SuppreMol's lead candidate SM101 is a recombinant, soluble, non-glycosylated version of the Fc γ receptor IIb. The protein binds to autoantibody/autoantigen complexes and blocks the triggering of Fc receptors on the surface of immune cells. As a result, the immune response is downregulated and the activation of the inflammation cascade typically seen in autoimmune diseases is prevented.

SM101 has been validated in relevant animal models and has shown strong efficacy in terms of decrease in inflammation and immune reaction.

At present, SM101 is being developed in Primary Immune Thrombocytopenia (ITP). SuppreMol has been granted orphan medicinal product designation in the EU as well as orphan drug designation in the US for this indication. The company believes SM101 may also have potential in Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) and other autoimmune diseases.

About MIG AG

MIG AG is a Munich-based venture capital firm with an investment focus on early to mid-stage life science and technology companies in German-speaking Europe. The funds currently managed by MIG amount to a total volume of 500 million Euros. More detailed information on MIG and MIG's investment portfolio can be found at www.mig-fonds.de and www.mig.ag.

About BioMedPartners AG

BioMedPartners AG is an independent healthcare-dedicated investment firm based in Basel, Switzerland, that provides private equity and mezzanine financing to private early- to mid-

stage healthcare and life science companies in Switzerland and neighboring regions (Alpine Rim). Since 2003, BioMedPartners have invested in over 30 companies, several of which have already successfully completed an IPO (Arpida AG, Santhera AG, Evolva Holding AG), or a trade sale (ESBATEch AG, Glycart Biotechnology AG). BioMedPartners currently manage three funds (BioMedInvest I & II and BioMedCredit). With total funds of more than CHF 250 million under management and a strong team of experienced specialists and industry experts, BioMedPartners have established themselves as one of the leading early-stage investors in Europe. BioMedPartners currently invest out of the BioMedInvest II LP fund, which has a size of CHF 106 million and was closed in 2009.

For additional information please visit: www.biomedvc.com

Contact

Dr Peter Buckel, CEO
SuppreMol GmbH
Am Klopferspitz 19
D-82152 Martinsried-Munich / Germany
Tel +49 (0)89 30 90 50 680
Fax +49 (0)89 30 90 50 68 68
info@suppremol.com
www.suppremol.com

Lead Investor Contacts

Michael Motschmann
MIG AG
Ismaninger Str. 102
D-81675 Munich / Germany
Tel +49 (0)89 98 57 06
Fax +49 (0)89 981 01 72
mm@mig.ag
www.mig.ag

Dr Markus Hosang, General Partner
BioMedPartners AG
Elisabethenstrasse 23
CH-4051 Basel / Switzerland
Tel +41 61 270 35 63
Fax +41 61 270 35 00
hosang@biomedvc.com
www.biomedvc.com